USPTO serial 99834815
BAXALTA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- ELTON, DAVID JONATHAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with BAXALTA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Bannockburn, IL, US
Bannockburn, IL, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karl M. Zielaznicki
Karl M. Zielaznicki Troutman Pepper Locke LLP875 Third Avenuec/o IP Services NYCNew York, NY 10022Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, substances and products for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceuticals for the treatment of blood diseases and disorders, immuno deficiency disorders, cancer; pharmaceutical preparations, namely, proteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, all containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteral, intramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparations, namely, chemotherapeutic agents | ACTIVE | — |
| 010 | Medical devices, namely, devices for reconstituting dried pharmaceuticals; medical apparatus and instruments, namely, medical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations. | ACTIVE | — |
| 044 | Medical services and health care; health care services, namely, providing care for human health; medical services, namely, human blood component collection services; medical services, namely, blood purification; medical services, namely, providing medical information in the field of oncology, immunology and hematology via a website; providing an online database for identifying the optimal dosage of medications for patients; medical services, namely, providing free trial prescription service programs for pharmaceutical preparations for the treatment of blood disorders. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 13, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 7, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 15, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 15, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 31, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 20, 2026 | NWAP | NEW APPLICATION ENTERED | — |